GLP-1 Bridge Program Extended for Medicare

CMS announced April 21 that it is delaying implementation of the Medicare Part D portion of the BALANCE Model for 2027 pending further evaluation and data collection. The Medicare GLP-1 Bridge will be extended through December 31, 2027, providing eligible Medicare Part D beneficiaries with access to certain GLP-1 drugs and allowing CMS to collect additional data on GLP-1 utilization to share with Part D plan sponsors ahead of potential implementation of BALANCE in Part D.

Objective Facts

On April 21, 2026, CMS announced that it is delaying implementation of the Medicare Part D portion of the BALANCE Model for 2027 pending further evaluation and data collection. The administration will shelve plans for a five-year experiment known as BALANCE, in which participating private Medicare insurers would have paid for drugs like Zepbound and Wegovy as a regular benefit. While CMS sought robust participation of Part D plan sponsors in the BALANCE model, which was voluntary for plans, interest appears to have fallen short of the targeted level. Although GLP-1 drug manufacturers agreed to a $245 net price, a substantial discount off prevailing list prices, savings to plans from a lower price may have been insufficient to offset higher costs associated with an uptake in GLP-1 use for obesity treatment. Instead, the Medicare GLP-1 Bridge will be extended through December 31, 2027, providing eligible Medicare Part D beneficiaries with access to certain GLP-1 drugs and allowing CMS to collect additional data on GLP-1 utilization to share with Part D plan sponsors ahead of potential implementation of BALANCE in Part D. Medicare will still cover the drugs for weight loss through a transitional program starting in July and running through the end of 2027, but it will foot the bill on its own.

Left-Leaning Perspective

Left-leaning and progressive health policy analysts have focused on the barriers to access created by the Bridge's design flaws. KFF highlighted that for beneficiaries enrolled in the Low-Income Subsidy (LIS) program, the LIS cost-sharing subsidies will not apply in the Medicare GLP-1 Bridge, which may make it more difficult for low- and modest-income beneficiaries who are otherwise eligible to participate to take advantage of coverage under the short-term demonstration in 2026 if the $50 monthly copayment is unaffordable. Axios reported that without the pilot program, Medicare patients who have been prescribed GLP-1s for weight loss can't count a $50 co-pay towards their deductible or out-of-pocket maximum, a change that could pose a financial barrier for some. Progressive health policy voices have also emphasized the coverage continuity problem: KFF notes that for participating beneficiaries to maintain Medicare coverage of their GLP-1 medication for obesity after the Medicare GLP-1 Bridge ends at the end of 2026, they will need to be enrolled in a Part D plan that chooses to participate in the BALANCE Model in 2027, which could mean having to switch Part D plans for the coming year, with potential cost and coverage implications for other medications beneficiaries use. This reflects progressive concern that beneficiaries who begin treatment under the mandatory Bridge program may face disruption and loss of coverage. Progressive coverage has largely been limited to policy analysis outlets like KFF and health news sources, which tend to focus on structural inequities rather than explicit partisan criticism of the Trump administration's approach. The left frames the fundamental issue as one of equity and access for vulnerable populations, and questions whether the Bridge—despite maintaining the $50 copay—adequately serves Medicare's most at-risk beneficiaries.

Right-Leaning Perspective

Right-leaning and business-focused analysis has emphasized that the BALANCE delay reflects rational insurers declining participation in an untenable financial arrangement. Axios reported that UnitedHealth CEO of government programs Bobby Hunter cited concerns about the initiative, stating 'We would like to find a path to yes on coverage over time, but there are some notable challenges and outstanding questions with the currently planned structure.' This framing positions plan sponsors as prudent risk managers rather than obstructionist actors. Raymond James analyst Chris Meekins argued that the bridge program will give CMS time to find a path forward for the BALANCE pilot and still help beneficiaries access the drugs at lower costs, writing 'This is a win for plan sponsors, [Eli Lilly and Novo Nordisk], as well as for Medicare beneficiaries.' Eli Lilly also stated that the extension 'provides an important opportunity to continue reaching patients who can benefit from GLP-1 therapies today.' Right-leaning coverage emphasizes that maintaining the Bridge ensures beneficiaries retain affordable access while providing insurers and manufacturers time to develop a sustainable long-term model. The right frames the issue as about fiscal responsibility and market reality: Although GLP-1 drug manufacturers agreed to a $245 net price, savings to plans from a lower price may have been insufficient to offset higher costs associated with an uptake in GLP-1 use for obesity treatment, and plans would have been at some financial risk if their actual costs for covering GLP-1s were higher than they expected.

Deep Dive

The April 21 BALANCE delay marks a critical pivot point in how Medicare approaches obesity drug coverage. Originally, the Trump administration announced the BALANCE model in December 2025 as a "five-year experiment" in which private Part D plans would voluntarily participate in covering GLP-1 drugs for weight loss if manufacturers agreed to a $245 monthly net price (with beneficiaries paying only $50). The model required 80% of Part D enrollment to be covered by participating plans for launch to proceed. The memo announcing the delay hit HPMS on April 21, 2026, which was exactly one day after the application deadline for Part D parent organizations. Far fewer plans than needed committed to participation, leaving the model unviable. The root cause reveals a genuine policy design problem: BALANCE was announced less than six months before 2027 plan bids are due to CMS on June 1, 2026. Because GLP-1s for weight loss have never been covered under Part D, there is no existing claims data to reliably estimate how many Medicare beneficiaries may qualify under the model and its impact on uptake and utilization of GLP-1s. Without this data to anchor projections, plan sponsors faced considerable uncertainty in accurately estimating their expected drug spend, pricing competitive bids, and setting appropriate beneficiary premiums with expanded GLP-1 coverage. A related concern was the risk of adverse selection among participating plans. Plans that opted into BALANCE may have faced a higher-than-average concentration of beneficiaries taking GLP-1s for weight loss, which could have resulted in higher plan costs. To address the risk of adverse selection and limit financial burden associated with higher-than-average GLP-1 utilization, CMS established a minimum participation threshold in order to proceed with BALANCE (i.e., at least 80% of Part D beneficiaries were enrolled in a participating plan) and provided narrowed risk corridors in select circumstances. Even with these risk mitigation strategies in place, BALANCE may not have provided sufficient incentives for broad voluntary plan participation. Both the left and right identify real tradeoffs. The left emphasizes that the Bridge extension, while maintaining a $50 copay, creates structural barriers: low-income beneficiaries in the LIS program cannot use their subsidies under the Bridge, which may make it more difficult for low- and modest-income beneficiaries who are otherwise eligible to participate to take advantage of coverage if the $50 monthly copayment is unaffordable. The right emphasizes that insurance plans cannot operate without actuarial predictability, and that although GLP-1 drug manufacturers agreed to a $245 net price, savings to plans from a lower price may have been insufficient to offset higher costs associated with an uptake in GLP-1 use for obesity treatment. Plans would also have been at some financial risk if their actual costs for covering GLP-1s were higher than they expected. Higher costs for Part D plans under the BALANCE model would have translated to higher federal spending and increased Part D premiums for enrollees. Both perspectives miss the core innovation opportunity: whether Medicare should have used its Medicare Advantage integrated care models or other risk-sharing structures to absorb GLP-1 uncertainty rather than asking private plans to accept unquantifiable risk. The near-term watch list includes the July 31, 2026 Medicaid application deadline. How many states apply, which states, and what their projected enrollment looks like will tell observers how serious the Medicaid leg of BALANCE becomes in the real world. The states that move first will create the early evidence base that CMS uses to argue for a Medicare relaunch.

OBJ SPEAKING

Create StoryTimelinesVoter ToolsRegional AnalysisAll StoriesCommunity PicksUSWorldPoliticsBusinessHealthEntertainmentTechnologyAbout

GLP-1 Bridge Program Extended for Medicare

CMS announced April 21 that it is delaying implementation of the Medicare Part D portion of the BALANCE Model for 2027 pending further evaluation and data collection. The Medicare GLP-1 Bridge will be extended through December 31, 2027, providing eligible Medicare Part D beneficiaries with access to certain GLP-1 drugs and allowing CMS to collect additional data on GLP-1 utilization to share with Part D plan sponsors ahead of potential implementation of BALANCE in Part D.

Apr 21, 2026· Updated Apr 27, 2026
What's Going On

On April 21, 2026, CMS announced that it is delaying implementation of the Medicare Part D portion of the BALANCE Model for 2027 pending further evaluation and data collection. The administration will shelve plans for a five-year experiment known as BALANCE, in which participating private Medicare insurers would have paid for drugs like Zepbound and Wegovy as a regular benefit. While CMS sought robust participation of Part D plan sponsors in the BALANCE model, which was voluntary for plans, interest appears to have fallen short of the targeted level. Although GLP-1 drug manufacturers agreed to a $245 net price, a substantial discount off prevailing list prices, savings to plans from a lower price may have been insufficient to offset higher costs associated with an uptake in GLP-1 use for obesity treatment. Instead, the Medicare GLP-1 Bridge will be extended through December 31, 2027, providing eligible Medicare Part D beneficiaries with access to certain GLP-1 drugs and allowing CMS to collect additional data on GLP-1 utilization to share with Part D plan sponsors ahead of potential implementation of BALANCE in Part D. Medicare will still cover the drugs for weight loss through a transitional program starting in July and running through the end of 2027, but it will foot the bill on its own.

Left says: Progressives emphasize that the Bridge's $50 copay excludes low-income beneficiaries from subsidies and doesn't count toward deductibles, while plan uncertainty threatens coverage continuity.
Right says: Conservatives and insurers frame the delay as pragmatic—private insurers face unsustainable financial risk under the BALANCE model, and the Bridge extension with federal funding is a workable interim solution that still delivers affordable access.
✓ Common Ground
Several voices across the aisle acknowledge that the Medicare GLP-1 Bridge extension through December 31, 2027, will provide eligible Medicare Part D beneficiaries with access to certain GLP-1 drugs and allow CMS to collect additional data on GLP-1 utilization.
Both left and right-leaning sources agree that under the Bridge program, eligible beneficiaries can get Medicare coverage of GLP-1s for obesity for a $50 copay.
Mainstream analysts across perspectives recognize that because GLP-1s for weight loss have never been covered under Part D, there is no existing claims data to reliably estimate how many Medicare beneficiaries may qualify under the model and its impact on uptake and utilization of GLP-1s. Without this data to anchor projections, plan sponsors faced considerable uncertainty in accurately estimating their expected drug spend, pricing competitive bids, and setting appropriate beneficiary premiums with expanded GLP-1 coverage. CMS noted that the extension of GLP-1 Bridge would provide plans with additional data to transition to potential BALANCE implementation in the future.
Both perspectives acknowledge that Medicare will still cover the drugs for weight loss through a transitional program starting in July and running through the end of 2027.
Objective Deep Dive

The April 21 BALANCE delay marks a critical pivot point in how Medicare approaches obesity drug coverage. Originally, the Trump administration announced the BALANCE model in December 2025 as a "five-year experiment" in which private Part D plans would voluntarily participate in covering GLP-1 drugs for weight loss if manufacturers agreed to a $245 monthly net price (with beneficiaries paying only $50). The model required 80% of Part D enrollment to be covered by participating plans for launch to proceed. The memo announcing the delay hit HPMS on April 21, 2026, which was exactly one day after the application deadline for Part D parent organizations. Far fewer plans than needed committed to participation, leaving the model unviable.

The root cause reveals a genuine policy design problem: BALANCE was announced less than six months before 2027 plan bids are due to CMS on June 1, 2026. Because GLP-1s for weight loss have never been covered under Part D, there is no existing claims data to reliably estimate how many Medicare beneficiaries may qualify under the model and its impact on uptake and utilization of GLP-1s. Without this data to anchor projections, plan sponsors faced considerable uncertainty in accurately estimating their expected drug spend, pricing competitive bids, and setting appropriate beneficiary premiums with expanded GLP-1 coverage. A related concern was the risk of adverse selection among participating plans. Plans that opted into BALANCE may have faced a higher-than-average concentration of beneficiaries taking GLP-1s for weight loss, which could have resulted in higher plan costs. To address the risk of adverse selection and limit financial burden associated with higher-than-average GLP-1 utilization, CMS established a minimum participation threshold in order to proceed with BALANCE (i.e., at least 80% of Part D beneficiaries were enrolled in a participating plan) and provided narrowed risk corridors in select circumstances. Even with these risk mitigation strategies in place, BALANCE may not have provided sufficient incentives for broad voluntary plan participation.

Both the left and right identify real tradeoffs. The left emphasizes that the Bridge extension, while maintaining a $50 copay, creates structural barriers: low-income beneficiaries in the LIS program cannot use their subsidies under the Bridge, which may make it more difficult for low- and modest-income beneficiaries who are otherwise eligible to participate to take advantage of coverage if the $50 monthly copayment is unaffordable. The right emphasizes that insurance plans cannot operate without actuarial predictability, and that although GLP-1 drug manufacturers agreed to a $245 net price, savings to plans from a lower price may have been insufficient to offset higher costs associated with an uptake in GLP-1 use for obesity treatment. Plans would also have been at some financial risk if their actual costs for covering GLP-1s were higher than they expected. Higher costs for Part D plans under the BALANCE model would have translated to higher federal spending and increased Part D premiums for enrollees. Both perspectives miss the core innovation opportunity: whether Medicare should have used its Medicare Advantage integrated care models or other risk-sharing structures to absorb GLP-1 uncertainty rather than asking private plans to accept unquantifiable risk.

The near-term watch list includes the July 31, 2026 Medicaid application deadline. How many states apply, which states, and what their projected enrollment looks like will tell observers how serious the Medicaid leg of BALANCE becomes in the real world. The states that move first will create the early evidence base that CMS uses to argue for a Medicare relaunch.

◈ Tone Comparison

Left-leaning outlets emphasize structural barriers and vulnerable populations, using phrases like "may make it more difficult" and highlighting gaps in coverage. Right-leaning outlets use pragmatic business language, focusing on "financial risk," "uncertainty," and "workable interim solutions" that balance multiple stakeholder interests. Both acknowledge the $50 copay as meaningful, but diverge sharply on whether the Bridge's external structure and income-based exclusions constitute adequate policy.